{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:15:58Z","timestamp":1790471758097,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"am","delay-in-days":281,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2018.01.042","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:18:39Z","timestamp":1517404719000},"page":"264-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays"],"prefix":"10.1016","volume":"133","author":[{"given":"Hideaki","family":"Yano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl A.","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie N.","family":"Schneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ara M.","family":"Abramyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Fant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Conrad","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4812-9474","authenticated-orcid":false,"given":"Amy H.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-096X","authenticated-orcid":false,"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.01.042_bib1","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1021\/acschemneuro.7b00094","article-title":"The isomeric preference of an atypical dopamine transporter inhibitor contributes to its selection of the transporter conformation","volume":"8","author":"Abramyan","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib2","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1021\/jm970525a","article-title":"Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter","volume":"40","author":"Agoston","year":"1997","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-319-50174-1_11","article-title":"Sigma-1 receptor agonists and their clinical implications in neuropsychiatric disorders","volume":"964","author":"Albayrak","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib4","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1073\/pnas.1705154114","article-title":"Identification of the gene that codes for the sigma2 receptor","volume":"114","author":"Alon","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0896-6273(02)00677-3","article-title":"The sigma receptor as a ligand-regulated auxiliary potassium channel subunit","volume":"34","author":"Aydar","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib6","doi-asserted-by":"crossref","first-page":"18219","DOI":"10.1523\/JNEUROSCI.3360-13.2013","article-title":"The sigma-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1\/GluN2A NMDA receptor","volume":"33","author":"Balasuriya","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib7","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/nn.2146","article-title":"The binding sites for cocaine and dopamine in the dopamine transporter overlap","volume":"11","author":"Beuming","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuropharm.2010.08.021","article-title":"The binding sites for benztropines and dopamine in the dopamine transporter overlap","volume":"60","author":"Bisgaard","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib9","first-page":"117","article-title":"[3H]-(+)-Pentazocine: a potent and highly selective benzomorphan-based probe for sigma-1 receptors","volume":"3","author":"Bowen","year":"1993","journal-title":"Mol. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib10","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1021\/jm400660u","article-title":"Structure of the sigma1 receptor and its ligand binding site","volume":"56","author":"Brune","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib11","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1021\/acs.jctc.6b00201","article-title":"Prediction of protein-ligand binding poses via a combination of induced fit docking and metadynamics simulations","volume":"12","author":"Clark","year":"2016","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib12","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/0024-3205(86)90640-5","article-title":"Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain","volume":"38","author":"Ferris","year":"1986","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pharmthera.2010.04.003","article-title":"Sigma receptors: potential targets for a new class of antidepressant drug","volume":"127","author":"Fishback","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib14","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1021\/bi800564j","article-title":"Probing the steroid binding domain-like I (SBDLI) of the sigma-1 receptor binding site using N-substituted photoaffinity labels","volume":"47","author":"Fontanilla","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3458.2004.tb00001.x","article-title":"Review of the pharmacological and clinical profile of rimcazole","volume":"10","author":"Gilmore","year":"2004","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/jm401529t","article-title":"Predicting the antinociceptive efficacy of sigma(1) receptor ligands by a novel receptor fluorescence resonance energy transfer (FRET) based biosensor","volume":"57","author":"Gomez-Soler","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib17","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/mp200368p","article-title":"Membrane and nuclear permeabilization by polymeric pDNA vehicles: efficient method for gene delivery or mechanism of cytotoxicity?","volume":"9","author":"Grandinetti","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib18","doi-asserted-by":"crossref","first-page":"20333","DOI":"10.1074\/jbc.M113.537993","article-title":"The oligomeric states of the purified sigma-1 receptor are stabilized by ligands","volume":"289","author":"Gromek","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00441-013-1774-8","article-title":"Sigma receptor 1 modulates ER stress and Bcl2 in murine retina","volume":"356","author":"Ha","year":"2014","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib20","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1073\/pnas.93.15.8072","article-title":"Purification, molecular cloning, and expression of the mammalian sigma1-binding site","volume":"93","author":"Hanner","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.117.241109","article-title":"Sigma receptor effects of N-Substituted benztropine analogs: implications for antagonism of cocaine self-administration","volume":"362","author":"Hiranita","year":"2017","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib24","doi-asserted-by":"crossref","first-page":"11250","DOI":"10.1074\/jbc.M116.774075","article-title":"The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats","volume":"292","author":"Hong","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib25","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1093\/nar\/gkg460","article-title":"Comparative protein structure modeling by iterative alignment, model building and model assessment","volume":"31","author":"John","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/164_2016_94","article-title":"A\u00a0role for sigma receptors in stimulant self-administration and addiction","volume":"244","author":"Katz","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/FBP.0000000000000209","article-title":"A\u00a0role for sigma receptors in stimulant self-administration and addiction","volume":"27","author":"Katz","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1124\/jpet.103.060525","article-title":"Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands","volume":"309","author":"Katz","year":"2004","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.tins.2012.09.007","article-title":"The sigma-1 receptor: roles in neuronal plasticity and disease","volume":"35","author":"Kourrich","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1124\/pr.110.004309","article-title":"Fluorescence\/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling","volume":"64","author":"Lohse","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1124\/mol.107.039800","article-title":"Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors","volume":"73","author":"Loland","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib32","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/bioinformatics\/btk023","article-title":"OPM: orientations of proteins in membranes database","volume":"22","author":"Lomize","year":"2006","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.tips.2007.06.007","article-title":"Resonance energy transfer approaches in molecular pharmacology and beyond","volume":"28","author":"Marullo","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib34","doi-asserted-by":"crossref","DOI":"10.1007\/164_2017_15","article-title":"Sigma-1 (sigma1) receptor in memory and neurodegenerative diseases","author":"Maurice","year":"2017","journal-title":"Handb exp pharmacol"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of sigma-1 receptors","volume":"124","author":"Maurice","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib36","article-title":"APEX2- tagging of Sigma 1-receptor indicates subcellular protein topology with cytosolic N-terminus and ER luminal C-terminus","author":"Mavylutov","year":"2017","journal-title":"Protein & Cell"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-3-319-50174-1_8","article-title":"Pharmacological modulation of the sigma 1 receptor and the treatment of pain","volume":"964","author":"Merlos","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1021\/acs.jmedchem.6b01148","article-title":"Toward understanding the structural basis of partial agonism at the dopamine D3 receptor","volume":"60","author":"Michino","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib39","doi-asserted-by":"crossref","first-page":"8618","DOI":"10.1039\/C5CC02204E","article-title":"Structural basis for Na(+)-sensitivity in dopamine D2 and D3 receptors","volume":"51","author":"Michino","year":"2015","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.nbd.2014.11.005","article-title":"Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease","volume":"74","author":"Miki","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1042\/BJ20141321","article-title":"The sigma-1 receptors are present in monomeric and oligomeric forms in living cells in the presence and absence of ligands","volume":"466","author":"Mishra","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-3-319-50174-1_10","article-title":"Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of Sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection","volume":"964","author":"Nguyen","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bbrc.2013.04.055","article-title":"A\u00a0sigma-1 receptor antagonist (NE-100) prevents tunicamycin-induced cell death via GRP78 induction in hippocampal cells","volume":"434","author":"Ono","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib44","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.febslet.2015.01.033","article-title":"Solution NMR studies reveal the location of the second transmembrane domain of the human sigma-1 receptor","volume":"589","author":"Ortega-Roldan","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib45","doi-asserted-by":"crossref","first-page":"21448","DOI":"10.1074\/jbc.M113.450379","article-title":"Characterization of the human sigma-1 receptor chaperone domain structure and binding immunoglobulin protein (BiP) interactions","volume":"288","author":"Ortega-Roldan","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-319-50174-1_3","article-title":"A\u00a0review of the human Sigma-1 receptor structure","volume":"964","author":"Ossa","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib47","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/neu.2010.1674","article-title":"Sigma receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury","volume":"28","author":"Penas","year":"2011","journal-title":"J.\u00a0Neurotrauma"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nprot.2006.52","article-title":"Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions","volume":"1","author":"Pfleger","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/bs.apha.2015.11.003","article-title":"Antinociception by Sigma-1 receptor antagonists: central and peripheral effects","volume":"75","author":"Romero","year":"2016","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10799893.2015.1015737","article-title":"Sigma receptors [sigmaRs]: biology in normal and diseased states","author":"Rousseaux","year":"2015","journal-title":"J.\u00a0Recept. Signal Transduct. Res."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-3-319-50174-1_13","article-title":"Sigma receptors and substance use disorders","volume":"964","author":"Sabino","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib52","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41467-017-02087-x","article-title":"The sigma-1 receptor modulates methamphetamine dysregulation of dopamine neurotransmission","volume":"8","author":"Sambo","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-319-50174-1_9","article-title":"Sigma-1 receptor antagonists: a new class of neuromodulatory analgesics","volume":"964","author":"Sanchez-Fernandez","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nature17391","article-title":"Crystal structure of the human sigma1 receptor","volume":"532","author":"Schmidt","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib55","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0024-3205(95)00073-9","article-title":"The effects of sigma ligands on protein release from lacrimal acinar cells: a potential agonist\/antagonist assay","volume":"56","author":"Schoenwald","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib56","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nbt.1671","article-title":"Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements","volume":"28","author":"Schroder","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib57","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib58","doi-asserted-by":"crossref","first-page":"31270","DOI":"10.1074\/jbc.M109.054809","article-title":"Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of \u201cselective\u201d antagonists","volume":"284","author":"Sohy","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-319-50174-1_6","article-title":"Sigma 1 receptor and ion channel dynamics in cancer","volume":"964","author":"Soriani","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib60","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0022-3565(25)33330-6","article-title":"Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in Guinea-pig brain","volume":"223","author":"Su","year":"1982","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib61","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.tips.2016.01.003","article-title":"The Sigma-1 receptor as a pluripotent modulator in living systems","volume":"37","author":"Su","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib62","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1073\/pnas.81.17.5618","article-title":"Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in Guinea pig brain membranes","volume":"81","author":"Tam","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib63","first-page":"125","article-title":"A\u00a0role for sigma binding in the antipsychotic profile of BMY 14802?","volume":"133","author":"Taylor","year":"1993","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib64","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nchembio.623","article-title":"CODA-RET reveals functional selectivity as a result of GPCR heteromerization","volume":"7","author":"Urizar","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-3-319-50174-1_18","article-title":"The role of Sigma1R in mammalian retina","volume":"964","author":"Wang","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2018.01.042_bib66","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.str.2015.10.012","article-title":"Close and allosteric opening of the polypeptide-binding site in a human Hsp70 chaperone BiP","volume":"23","author":"Yang","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.neuropharm.2018.01.042_bib67","series-title":"Luciferase Complementation Based Detection of G Protein Coupled Receptor Activity","author":"Yano","year":"2018"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:54:58Z","timestamp":1762214098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818300480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":67,"alternative-id":["S0028390818300480"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.042","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}